This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • The effect of everolimus on retinal pigment epithelium and proliferative vitreo-retinopathy

The effect of everolimus on retinal pigment epithelium and proliferative vitreo-retinopathy
Reviewed by Kurt Spiteri Cornish

1 August 2018 | Kurt Spiteri Cornish | EYE - Vitreo-Retinal

The principal cells involved in proliferative vitreo-retinopathy (PVR) are retinal pigment epithelial cells (RPE). Everolimus is a drug used in renal cell carcinoma which targets and inhibits a key regulatory protein in cancer (mTOR). In this study, the authors investigated the effect of everolimus on RPE cells and modification of the severity of experimental PVR induced by RPE cells. In the in vitro studies, everolimus significantly inhibited the proliferation and migration of RPE cells. In the in vivo studies (utilising rabbits with experimental PVR), 12 control eyes and 11 study eyes were included. Oral everolimus (0.5mg/day) suppressed the expression of mTOR in PVR, but there was no statistical difference in PVR grading between the study and control groups at all time points. This means that the drug did not show any effect in suppressing the experimental PVR. The authors conclude that this study does not exclude the role of everolimus or other mTOR inhibitors in clinical PVR. They highlight the difference between experimental and clinical PVR, and that PVR formation is multifactorial, in which the significance of mTOR is unknown. Further studies are needed to further investigate PVR therapies. 

Evaluation of the effect of everolimus on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy.
Kuo HK, Chen YH, Kuo YH, et al.
CURRENT EYE RESEARCH
2018;43:333-9.
Share This
CONTRIBUTOR
Kurt Spiteri Cornish

Sheffield Teaching Hospitals NHS Trust, London, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency